NYSE:AMAM Ambrx Biopharma (AMAM) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$28.00▼$28.0050-Day Range$27.70▼$28.0052-Week Range$6.55▼$28.15VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$23.29 Stock AnalysisStock AnalysisAnalyst ForecastsHeadlinesInsider TradesOwnershipTrendsStock AnalysisAnalyst ForecastsHeadlinesInsider TradesOwnershipTrends Get Ambrx Biopharma alerts: Email Address Ambrx Biopharma MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside16.8% Downside$23.29 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.45) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.04 out of 5 starsMedical Sector905th out of 910 stocksBiological Products, Except Diagnostic Industry154th out of 155 stocks 1.2 Analyst's Opinion Consensus RatingAmbrx Biopharma has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAmbrx Biopharma has received no research coverage in the past 90 days.Read more about Ambrx Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AMAM. Previous Next 0.0 Dividend Strength Dividend YieldAmbrx Biopharma does not currently pay a dividend.Dividend GrowthAmbrx Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMAM. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for AMAM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Ambrx Biopharma is held by insiders.Percentage Held by Institutions77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ambrx Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.45) to ($1.28) per share.Price to Book Value per Share RatioAmbrx Biopharma has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Ambrx Biopharma Stock (NYSE:AMAM)Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Read More Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video AMAM Stock News HeadlinesAugust 31, 2024 | benzinga.comCormorant Global Healthcare Master Fund, LP's Net WorthMay 24, 2024 | finance.yahoo.com14 Day AMERIBOR Average Rate (^AMBRX)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.April 5, 2024 | benzinga.comLatest News for Johnson & Johnson Stock (NYSE:JNJ)March 7, 2024 | finanznachrichten.deAmbrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & JohnsonMarch 7, 2024 | markets.businessinsider.comJohnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash DealMarch 6, 2024 | globenewswire.comAmbrx Shareholders Approve Acquisition by Johnson & JohnsonFebruary 23, 2024 | investorplace.com3 Stocks to Buy That Are Up 200% or More in 2024September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.February 20, 2024 | msn.comIs Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?February 12, 2024 | stockhouse.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAMFebruary 10, 2024 | businesswire.comAMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARPJanuary 11, 2024 | msn.comJMP Securities Downgrades Ambrx Biopharma (AMAM)January 10, 2024 | realmoney.thestreet.comAmbrx Biopharma just downgraded at JMP Securities, here's whyJanuary 9, 2024 | finance.yahoo.comAmbrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&JJanuary 8, 2024 | nasdaq.comJ&J to buy cancer therapy developer Ambrx for $2 blnJanuary 8, 2024 | tmcnet.comAMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to ShareholdersSee More Headlines Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AMAM CUSIPN/A CIK1836056 Webambrx.com Phone858-875-2400FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$23.29 High Stock Price Target$32.00 Low Stock Price Target$9.00 Potential Upside/Downside-16.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.28 Quick Ratio13.28 Sales & Book Value Annual Sales$7.40 million Price / Sales238.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book9.18Miscellaneous Outstanding Shares63,150,000Free Float62,746,000Market Cap$1.77 billion OptionableOptionable Beta-1.92 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Daniel J. O'Connor J.D. (Age 59)CEO, President & Director Comp: $509.94kMs. Sonja Nelson CPA (Age 51)Chief Financial Officer Comp: $1.18MMr. Andrew P. Aromando (Age 55)Chief Operating Officer Dr. Ying J. Buechler Ph.D.Chief Technology OfficerDr. Shawn Shao-Hui Zhang Ph.D.Chief Scientific Officer & GM of ChinaMr. Jared KellySenior VP, General Counsel & Corporate SecretaryMr. Robert AzzaraVice President of Human CapitalDr. Sandra Aung Ph.D.Chief Clinical OfficerMs. Renu Vaish M.Sc. (Age 57)Chief Regulatory Officer More ExecutivesKey CompetitorsKrystal BiotechNASDAQ:KRYSImmunovantNASDAQ:IMVTCRISPR TherapeuticsNASDAQ:CRSPADMA BiologicsNASDAQ:ADMADenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsidersDaniel J O'connorSold 50,012 sharesTotal: $491,117.84 ($9.82/share)Sonja NelsonSold 12,778 sharesTotal: $125,479.96 ($9.82/share)Cormorant Asset Management, LpBought 1,307,311 shares on 10/23/2023Total: $9.14 M ($6.99/share)Cormorant Asset Management, LpBought 751,233 shares on 9/18/2023Total: $6.94 M ($9.24/share)Cormorant Asset Management, LpBought 1,401,505 shares on 9/15/2023Total: $12.68 M ($9.05/share)View All Insider Transactions AMAM Stock Analysis - Frequently Asked Questions When did Ambrx Biopharma IPO? Ambrx Biopharma (AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO. This page (NYSE:AMAM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ambrx Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.